A Closer Look at Who’s Going to RESI

20 Mar

By Tom Crosby, RESI Conference Manager, LSN

Tom 2Next Monday, March 24th will mark the date for Life Science Nation’s second Redefining Early Stage Investments Conference in Boston’s State Room. Nearly 400 active early stage life science investors, biotech and medtech innovators, and senior executives from all segments of the industry will converge 33 floors above the city for a full day.

LSN’s motivation to create the RESI conference is based on a simple concept: while the world of early stage life science investments has fundamentally changed, many fundraising executives are still operating under the assumption that the old process for raising capital is still applicable. In light of this, LSN conceived the concept of a forum of entrepreneurs and active early stage investors not only to discuss the new marketplace, but also to initiate dialogues that would eventually lead to allocations. This is accomplished by a combination of top-tier investor panels, workshops, and a full-day partnering pavilion.

Ultimately, the key differentiator for RESI is that it is a targeted event seeking to connecting early stage technologies with investors – therapeutics, diagnostics, medtech, healthcare IT, and investors from 10 categories are all represented. It’s not indication specific, it’s not just for biotech, and it’s not just for medtech; it is the only conference that focuses on bridging the funding void that traditional investors have left.

So, what does RESI look like this time around? Let’s take a look at the numbers:

·         Total Attendees: 390 attendees from 377 organizations

·         Countries Represented:  12 different countries, and representation from across the US

TOM

Moreover, the ratio of investors to companies seeking capital is close to 1:1, which outperforms any other meeting on this scale of which LSN is aware. As a company – and as an conference – LSN and the RESI Conference continue to fill gaps in the market, create disruptive events, and ultimately, be an advocate for early stage companies seeking to move science forward.

Leave a comment